Inventaire - your friends and communities are your best library - Inventaire

Cites articles 18

Date

Title

Authors

2014-08-01

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study)

Roberta Lanzillo, Giuseppe Salemi, Paola Cavalla, Damiano Paolicelli, Maria Trojano, Maria Pia Sormani, Patrizia Sola, Angelo Ghezzi
2014-04-01

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study

Jerome de Seze, Helene Zephir
2014-09-25

Relapses in patients treated with fingolimod after previous exposure to natalizumab
2014-03-28

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Bianca Weinstock-Guttman, Hans-Peter Hartung, Ludwig Kappos, Ralf Gold, Bruce A C Cree
2014-03-07

Fingolimod after natalizumab and the risk of short-term relapse

Helmut Butzkueven, Danny Liew, Guillermo Izquierdo, Pierre Duquette, Raed Alroughani
2013-04-30

Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.

Frederik Barkhof, Giancarlo Comi, Guillermo Izquierdo
2012-12-25

Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.

Björn Tackenberg, Christian Eienbröker, Tania Kümpfel, Ralf Gold
2012-11-26

Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption

Gianluigi Mancardi, Antonio Uccelli
2012-11-01

Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings

Paolo Gallo
2012-06-28

Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab

Silvia Rossi, Diego Centonze, Valeria Studer, Gary R. Cutter
2011-03-23

De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate.

Lisa Ann Gerdes
2011-02

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Emmanuelle Waubant, Eva Havrdová, Alan J. Thompson, Massimo Filippi, Michael Hutchinson, Ludwig Kappos, Brian G Weinshenker, Chris Polman, Brenda L Banwell, Stephen C. Reingold, Kazuo Fujihara, Fred D. Lublin, Magnhild Sandberg-Wollheim, Jerry S Wolinsky
2010-02-04

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

Hans-Peter Hartung, Ludwig Kappos, Frederik Barkhof, Giancarlo Comi, Guillermo Izquierdo, James Jin, Bhupendra O Khatri, Xavier Montalban, Tracy Stites
2010-12-06

Course of relapsing-remitting multiple sclerosis before, during and after natalizumab
2010-09-01

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

Joep Killestein
2008-11-05

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy
2007-02-01

A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study

Peter Austin, Paul Grootendorst
2005-05

Estimating causal effects of public health education campaigns using propensity score methodology

Article - wd:Q41369754

Welcome to Inventaire

the library of your friends and communities

you are offline